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S U M M A R Y
Objectives: To compare the clinical and bacteriological effectiveness of intravenous (IV) ceftriaxone
followed by oral cefditoren pivoxil or IV ceftriaxone for acute pyelonephritis.
Methods: A prospective randomized controlled trial of patients with a presumptive diagnosis of acute
pyelonephritis was performed. Daily 2 g IV ceftriaxone was initially given to all patients. After day 3,
patients who satisﬁed the criteria for switch therapy were randomized to either group A (IV ceftriaxone)
or group B (oral cefditoren pivoxil 400 mg once daily).
Results: Eighty-two patients were enrolled; 41 (50%) patients in group A and 41 (50%) patients in group B
were evaluated. There was no statistically signiﬁcant difference in baseline characteristics between the
two groups. Clinical cure was observed in 39 of 41 (95.1%) patients in group A and 41 of 41 (100%)
patients in group B (p = 0.15, 95% conﬁdence interval (CI) 0.12 to 0.02). Urine bacteriological
eradication was found in 63.4% in group A and 60% in group B (p = 0.75, 95% CI 0.18 to 0.25). There was
no statistically signiﬁcant difference in adverse effects between the two treatment groups.
Conclusion: These data suggest that IV ceftriaxone followed by oral cefditoren pivoxil is highly effective
and well-tolerated for the treatment of acute pyelonephritis, even for uropathogens with a high
proportion of quinolone-resistant strains.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Acute pyelonephritis is among the most commonly encoun-
tered bacterial infections in women. The treatment of acute
pyelonephritis is often started empirically before the identiﬁcation
of the causal organisms. Hospitalization and the administration of
parenteral antibiotics have been the traditional treatment for this
disease,1,2 and this approach continues to be the recommended
standard of care. When appropriately treated, the majority of
patients hospitalized with pyelonephritis have a favorable
outcome. The most common causative pathogen of this disease
is Escherichia coli. The optimal duration of treatment for
acute pyelonephritis is 10–14 days.3,4 However, current practice
has changed to switch therapy – an oral antibiotic agent following
an intravenous antibiotic agent.5 Oral ﬂuoroquinolones have been
successfully used.1,3–5
Unfortunately an association between an increase in ﬂuoro-
quinolone prescriptions and an increase in the bacterial resistance* Corresponding author. Tel.: +66 43363654; fax: +66 43347542.
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Increasing ﬂuoroquinolone resistance in many uropathogens has
raised concerns about the future usefulness of this class of
antibiotics. Data from the National Antimicrobial Resistance
Surveillance Center of Thailand (NARST) in 2010 reported that E.
coli isolated from urine in outpatient settings showed an average
57.5% resistant to oﬂoxacin, which is classiﬁed as quinolone-
resistant E. coli (QREC).5,8 Therefore, this might lead to signiﬁcant
clinical failure. It is important that quinolone-sparing antibiotics
are used when appropriate. In the case of acute pyelonephritis,
beta-lactam antibiotics such as third-generation cephalosporins
have been advocated as quinolone-sparing agents.5,9 The efﬁcacy
of third-generation cephalosporins has been demonstrated in well-
designed clinical trials. Therefore, an intravenous cephalosporin as
monotherapy in hospitalized patients has been considered as a
recommended standard of treatment.5,10–12 However, more
interestingly, the question has been raised as to which oral
antimicrobial agent is appropriate for substitution when the
patient meets the criteria for switch therapy in the era of a high
incidence of QREC.
Cefditoren pivoxil is an advanced and broad-spectrum
oral third-generation cephalosporin. The major pharmacokineticses. Published by Elsevier Ltd. All rights reserved.
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distribution, with an average of 1 liter/kg, and the primary
excretion of unchanged drug through the urinary tract of
approximately 20% to 30%. After an oral 400-mg single dose, the
mean concentration in the urine is 186.5 mg/l at 2–4 h and
12.7 mg/l at 8–12 h, and it is a potential drug for use in the
treatment of acute pyelonephritis.13 Cefditoren pivoxil also
possesses excellent bactericidal activity against Gram-negative
and certain Gram-positive pathogens. It has shown excellent in
vitro activity against E. coli. In addition, other bacteria including
Klebsiella pneumoniae and Proteus mirabilis are susceptible to
cefditoren.13–17 Some studies have shown that the activity of
cefditoren against Enterobacteriaceae producing community-ac-
quired urinary tract infections (UTIs) is superior to that of
ciproﬂoxacin and cefuroxime, and similar to that of fosfomycin.14
However, there are few data on the efﬁcacy of this regimen for the
treatment of UTIs, and there is no published study on the efﬁcacy of
cefditoren pivoxil in the treatment of acute pyelonephritis in the
current era of high-level ﬂuoroquinolone resistance.
The aim of this study was to compare the clinical and
bacteriological effectiveness of intravenous ceftriaxone as a
standard intravenous antibiotic with switch therapy from intra-
venous ceftriaxone to oral cefditoren pivoxil, in the treatment of
acute pyelonephritis.
2. Materials and methods
2.1. Study design
A prospective, randomized, double dummy, placebo-controlled
trial was performed. The clinical trial was undertaken at Srinagarind
Hospital, a university hospital in Thailand. The study period was
from December 2010 to November 2011. It was conducted in
accordance with the guidelines of the Infectious Diseases Society of
America (IDSA) 2010 for the assessment of anti-infective drugs in the
treatment of acute pyelonephritis. Written informed consent was
obtained from all patients, and the institutional review board at the
participating site approved the protocol.
2.2. Patients
Both hospitalized and non-hospitalized patients were consid-
ered eligible if they: (1) were over 18 years of age; (2) had a
presumptive diagnosis of acute pyelonephritis deﬁned as one of
the following: presentation within 24–48 h including fever (body
temperature 38.0 8C), urinary syndrome (dysuria, urgency,
urinary frequency, suprapubic pain, or gross hematuria), and ﬂank
pain, in association with pyuria (>5 leukocytes per high-power
ﬁeld in urine analysis) and a positive urine culture and/or
hemoculture (bacteriuria was deﬁned as a colony count of >105
colony-forming units (CFU)/ml); (3) had an infection caused by a
uropathogen susceptible to the study drugs; (4) met the criteria for
switch therapy; and (5) voluntarily consented to be enrolled in the
study. Patients were excluded from the study if they: (1) had
severe renal impairment, had creatinine clearance less than 30 ml/
min, or had severe impairment of liver function, deﬁned as a serum
level of transaminase enzyme greater than 6 times the upper limit
of normal; (2) had an absolute neutrophil count of <1  109/l,
platelet concentration of <75  109/l, or hematocrit level of <25%;
(3) had an immune-compromising illness, rapidly progressive
disease, or serious disease such as malignancy that could
potentially shorten the life-span; (4) were being treated with
concomitant drug(s) such as corticosteroids and anti-inﬂammato-
ry drugs, which could potentially inﬂuence the evaluation of the
efﬁcacy of the study drug; (5) were pregnant or lactating; (6) had a
previous hypersensitivity to milk protein or cephalosporins, unlessthe patient had a history of mild rash to beta-lactams; (7) needed
concomitant antimicrobials in addition to the study drug, such as
ﬂuoroquinolones, co-trimoxazole, and amoxicillin with or without
beta-lactamase inhibitor; (8) had functional or structural abnor-
malities of the urinary tract, renal stone, or retained Foley’s
catheter; or (9) had had a UTI in the preceding 30 days.
Patients with a presumptive diagnosis of acute pyelonephritis
and without a history of penicillin or cephalosporin allergy were
given 2 g of ceftriaxone intravenously infused over 30 min once
daily as an initial antibiotic agent. After day 3, patients who
satisﬁed the inclusion criteria and the criteria for switch therapy
were enrolled and randomized to either the control or study group
regimens. Members of group A (control group) were given four oral
placebo tablets with a meal once daily plus 2 g of ceftriaxone
intravenously infused over 30 min (diluted in 100 ml of 0.9%
normal saline solution) once daily. Members of group B (study
group) were given four oral cefditoren pivoxil (100 mg) tablets
with a meal once daily plus an intravenous placebo intravenously
infused over 30 min once daily. The criteria for switch therapy
were as follows: (1) signs and symptoms of infection improved for
at least 24 h from the initial presentation; (2) functioning
gastrointestinal tract; (3) afebrile (body temperature 37.8 8C
by oral measurement); (4) trend towards normalized white blood
cell and neutrophil count values.18,19
The regular course of treatment was completed within 10 days.
The patients were randomized to either group A or group B by the
use of a computer-generated random number allocation schedule
and block size of four. Patients were discharged from hospital
when they had remained afebrile for 24 h. A follow-up visit was
scheduled after completion of day 10 (day 11). At the follow-up,
patients were re-evaluated for clinical signs and symptoms of
acute pyelonephritis by physical examination, including body
temperature, ﬂank pain measurement, and urinary syndrome.
Also, patients were questioned about side-effects and checked for
adherence to medication by observing the package of medicine
(pill-count technique) together with the drug administration
record form (self-report).
2.3. Laboratory procedures for measuring outcomes
2.3.1. Laboratory variables (complete blood count and blood
chemistry)
On admission, the patient’s acute inﬂammatory response was
assessed by total white blood cell count with differentiation. Other
laboratory variables such as serum creatinine and blood urea
nitrogen were used to assess renal function. In addition, aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) were
both measured at admission and after the end of treatment to
assess the safety proﬁle. The total white blood cell count with
differentiation was repeated at enrollment and at the follow-up
visit to assess the criteria for switch therapy and evaluate the
efﬁcacy of the study drug. Any signiﬁcant changes from baseline
were noted.
2.3.2. Urinalysis
Voided midstream urine specimens for the analysis of pyuria
were obtained on admission (before starting intravenous antibiotic
therapy) and at the follow-up visit. Examination included the
amount of white blood cells, leukocytes, leukocyte esterase, nitrite,
and bacteria. The amount of bacteria in the urine specimen was
classiﬁed as few, moderate, or numerous.
2.3.3. Urine culture
Voided midstream urine specimens for culture were obtained
on admission (before starting intravenous antibiotic therapy) and
at the follow-up visit to ensure a satisfactory response. All isolates
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Examination included identiﬁcation of pathogens, quantiﬁcation,
and susceptibility testing. Pathogens were tested for in vitro
susceptibility to cefditoren, ceftriaxone, cephalothin, cefotaxime,
ceftazidime, ampicillin, amikacin, gentamicin, co-trimoxazole,
norﬂoxacin, and oﬂoxacin by the disk diffusion method following
the Clinical and Laboratory Standards Institute (CLSI) 2010
guidelines and the Japan Antibiotics Drug Standard (JADS) 2008.
Bacteria were classiﬁed as being resistant to ceftriaxone if the
minimal inhibitory concentration (MIC) was 4 mg/l using the
CLSI 2010 susceptibility breakpoint.20 The resistance breakpoint
used for cefditoren was >1 mg/l.14
2.3.4. Blood culture
Blood specimens for aerobic culture were obtained on
admission (only for patients with presentation of sepsis syndrome)
and at the follow-up visit. All isolates were identiﬁed in the
laboratory of Srinagarind Hospital. Examinations included identi-
ﬁcation of pathogens and susceptibility testing.
2.4. Assessment of efﬁcacy
2.4.1. Clinical response
After enrollment, the clinical response to the study drug was
measured after 24 h of switch therapy, at the follow-up visit (day
11), and at 2 weeks after the end of treatment. The primary
outcome in this study was the clinical response at the completion
of study drug treatment (day 11). The clinical response was based
on the duration of body temperature, urinary syndrome, and ﬂank
pain. Each patient’s response was categorized as one of the
following: ‘cure’, deﬁned as resolution of all clinical symptoms and
signs of infection; ‘improvement’, deﬁned as normalization of body
temperature but persistence of either urinary syndrome or ﬂank
pain; ‘failure’, deﬁned as no normalization of temperature, the
development of shock at any time, or death, the patient requiring
additional antibacterial therapy to cure the infection, or substitu-
tion with other drug(s); or ‘indeterminate’, deﬁned as the patient
being lost before follow-up, or having died within 48 h after the
ﬁrst dose of the study drug for any reason, or having died after 48 h
because of non infectious-related reasons (as judged by the
investigators).
2.4.2. Bacteriological response
The bacteriological response as a secondary outcome was
assessed by quantitative urine culture at the completion of the
study drug treatment (day 11). The bacteriological response was
categorized as: ‘eradication’, deﬁned as eradication of the infecting
strain (not found at the follow-up visit) or yielding sterile urine
cultures; ‘persistence’, deﬁned as persistence of the infecting
strain, i.e. a urine culture with 104 CFU/ml concentration of any
uropathogen present in the admission culture; or ‘superinfection’,
deﬁned as the emergence of a new bacterial isolate (105 CFU/ml)
other than the baseline pathogen which was either susceptible or
resistant to the study drug. All other conditions were considered
‘indeterminate’, such as urine culture with mixed growth of 2
different organisms at the follow-up visit in any colony count.
2.5. Assessment of safety and tolerability
All patients who received one or more doses of the study drug
were evaluated for safety. Patients were monitored for adverse
events (AEs) during the study period and for 10 days after all study
drugs (parenteral and oral) were completed. The investigators
categorized the intensity of the AEs as mild, moderate, or severe,
and the likelihood of its relation to the study drug as unlikely,
possible, probable, or deﬁnite. The tolerability of study drugs wasevaluated by the investigators or a physician. The evaluation was
based on the investigator’s inspection and the patient’s comments
regarding the intensity of AEs. During the study period, the
physician could terminate the treatment based on clinical
judgment for safety or abnormal laboratory ﬁndings attributed
to the study drugs.
2.6. Statistical analysis
Results were analyzed using SPSS v. 15.0 and STATA v. 10.0
statistical programs. Values are presented as the mean  standard
deviation for continuous variables, or as the percentage of the group
from which they were derived for the categorical variables.
Categorical variables were compared between the two groups using
the proportion test. The unpaired t-test was used to analyze
continuous variables if the data were normally distributed. Equiva-
lence (non-inferiority) for this analysis was determined by the 95%
(two-sided test) conﬁdence interval (95% CI) for the difference in
response rates between the two groups. If the observed response rate
in the comparator group was more than 68.8%, for equivalence to be
demonstrated, the CI of the difference had to contain zero and its
lower limit could not be less than 25%. A p-value of <0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Patient characteristics
Characteristics of all the study patients are presented in Table 1.
One hundred and seven patients (102 women and ﬁve men) with a
presumptive diagnosis of acute pyelonephritis during the study
period, presenting on the ﬁrst day of admission, were considered for
enrollment (Figure 1). Twenty-ﬁve patients were not enrolled in the
study for the following reasons: seven patients did not have a
baseline causative pathogen, seven patients had negative urine and/
or blood cultures (no growth), three patients had E. coli with
extended-spectrum beta-lactamase (ESBL) in their urine cultures,
four patients did not have pyuria in their urine analysis, three
patients had Pseudomonas aeruginosa in their urine cultures, and one
patient had an allergic reaction to ceftriaxone during infusion and
was changed to ciproﬂoxacin. Of the remaining 82 patients, three
males and 79 females gave informed consent and were enrolled in
this clinical study.The 82 patients were randomized into either
group A (41 patients, 50%) or group B (41 patients, 50%), with a block
size of four regarding sex and current diagnosis. Baseline demo-
graphics, disease characteristics, and the clinical severities of both
groups were generally similar. A total of 20 (24.4%) patients in the
present study, including all the male patients, were diagnosed with
acute complicated pyelonephritis; the majority of these patients had
underlying diabetes mellitus or chronic kidney disease.
3.2. Baseline microbiology
The distribution of uropathogens in the randomized patients in
each treatment group and their susceptibility proﬁles were
comparable (Table 2). Of the 91 total isolates, E. coli was the most
common pathogen in the urine cultures, accounting for 83.5% of
the isolates. Other species of Enterobacteriaceae such as P. mirabilis,
K. pneumoniae, and Citrobacter diversus were the next most
frequent isolates (5/91; 5.5%). Gram-positive bacteria such as
Staphylococcus saprophyticus and Streptococcus spp were also
found. The distribution of isolates including Gram-positive and
Gram-negative bacteria indicated no signiﬁcant difference be-
tween the two groups. In addition, 24 of 76 E. coli strains (31.6%) in
the present study were quinolone-resistant: 13 of 40 (32.5%) in
group A and 11 of 36 (30.6%) in group B.
Table 1
A comparison of baseline characteristics between the two treatment groups
Characteristics Group A
(n = 41)a
Group B
(n = 41)a
p-Value
Age (years), mean  SD 48.63  18.90 41.71  20.11 0.1120
Gender
Male 1 (2.4) 2 (4.9) 0.5461
Female 40 (97.6) 39 (95.1) 0.5461
Current diagnosis
Acute uncomplicated PN 30 (73.2) 32 (78.0) 0.6128
Acute complicated PN 11 (26.8) 9 (22.0) 0.6128
Acute complicated PN
Diabetes mellitus 8 (19.5) 6 (14.6) 0.5552
Chronic kidney disease 2 (4.9) 1 (2.4) 0.5461
Symptoms duration before diagnosis (days), mean  SD 2.56  2.37 2.66  1.71 0.8312
Risk factors for antimicrobial-resistant uropathogens
Antimicrobials within 1 month before treatment 6 (14.6) 6 (14.6) 1.0000
History of previous upper or lower UTIs within 6 months 8 (19.5) 5 (12.2) 0.3655
Previous hospitalization within 3 months 3 (7.3) 2 (4.9) 0.6498
Clinical signs and symptoms
Fever (body temp. 38.0 8C) 36 (87.8) 38 (92.7) 0.4545
Chills 35 (85.4) 30 (73.2) 0.1728
Nausea and vomiting 14 (34.1) 16 (39.0) 0.6450
Urinary syndrome 35 (85.4) 38 (92.7) 0.2898
Flank pain 37 (90.2) 39 (95.1) 0.3952
Body temperature (8C), mean  SD 38.82  0.96 38.79  0.72 0.8926
Clinical severity
Marked severity 14 (34.1) 11 (26.8) 0.4726
Moderate severity 22 (53.7) 26 (63.4) 0.3727
Mild severity 5 (12.2) 4 (9.8) 0.7284
Types of infection
Monomicrobial infection 35 (85.4) 39 (95.1) 0.1387
Polymicrobial infection 6 (14.6) 2 (4.9) 0.2702
Bacteriuria (uropathogens) 39 (95.1) 38 (92.7) 0.6444
Bacteremia 11 (26.8) 6 (14.6) 0.1732
Duration of intravenous ceftriaxone therapy before enrollment (days), mean  SD 3.12  0.64 3.17  0.50 0.7005
Hematocrit level (%), mean  SD 35.12  5.37 35.72  5.59 0.6198
WBC in serum (109/l), mean  SD 14.49  7.13 12.72  3.91 0.1699
Neutrophils in serum (%), mean  SD 83.54  6.54 79.38  12.73 0.0675
Serum creatinine (mg/dl), mean  SD 0.88  0.35 0.78  0.23 0.1317
Number of hospitalized patients 19 (46.3) 12 (29.3) 0.1124
Number of non-hospitalized patients 22 (53.7) 29 (70.7) 0.1124
UTI, urinary tract infection; PN, pyelonephritis; SD, standard deviation; WBC, white blood cell count.
a Data for each characteristic represent the number and percentage (in parenthesis) of the patients, unless otherwise indicated.
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Figure 1. CONSORT ﬂow chart of enrollment of the patients with acute
pyelonephritis.
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hemocultures were available: 11 of 32 from group A and six of 23
from group B (p = not signiﬁcant (NS)). E. coli was the most
common pathogen grown from positive blood cultures, accounting
for 82.4% of all isolates.
3.3. Overall clinical efﬁcacy
The resolution of acute symptoms was achieved at the same
time in both groups and no statistically signiﬁcant differences were
observed in the duration of temperature, urinary syndrome, or
ﬂank pain. The overall clinical efﬁcacy as the primary outcome is
shown in Table 3. This was rated as cure, improvement, failure, or
indeterminate according to the clinical signs and symptoms that
patients presented at the follow-up visit. Results showed that the
clinical cure rates of group A and B were 95.1% (39/41 patients) and
100% (41/41 patients), respectively. No statistically signiﬁcant
difference was seen between the two groups (p = 0.15, 95% CI
0.12 to 0.02). One patient from group A was classiﬁed as
‘improvement’ because of persistent ﬂank pain. Another patient
from group A was classiﬁed as ‘failure’ because of recurrent fever
(body temperature >38.0 8C) on the third day of the study drug,
after the patient had been afebrile 24 h before enrollment. This
case was investigated by the physician to ﬁnd other sources of
infection. Unfortunately she was still suspected of having a UTI
without any source of infection. This case ﬁnally recovered
Table 2
Distribution of pathogens among the two groups, from urine and blood cultures isolates
Pathogens Group A Group B
Urine culture Blood culture Urine culture Blood culture
(n = 48)a (n = 11)a (n = 43)a (n = 6)a
Gram-negative bacteria
Escherichia coli 40 (83.3) 8 (72.7) 36 (83.7) 6 (100)
Proteus mirabilis 1 (2.1) – 2 (4.7) –
Klebsiella pneumoniae 1 (2.1) 1 (9.1) 0 –
Citrobacter diversus 1 (2.1) – 0 –
Gram-positive bacteria
Staphylococcus saprophyticus 1 (2.1) – 3 (7.0) –
Streptococcus spp 2 (4.2) 1 (9.1) 1 (2.3) –
Coagulase-negative staphylococci 1 (2.1) – 0 –
Enterococcus spp – 1 (9.1) – –
Other
Mixed growth of organismsb 1 (2.1) – 1 (2.3) –
a Data for each variable represent the number and percentage (in parenthesis), unless otherwise indicated.
b Bacterial colony count 103 to less than 105 CFU/ml with 3 different organisms.
Table 3
Clinical and bacteriological outcomes of the two treatment groups at the follow-up visit. Results are expressed as numbers and percentages (in parenthesis)
Outcomes Group A Group B Proportion difference (95% CI) p-Value
Clinical outcomes, number of patient/total (%)
Cure 39/41 (95.1) 41/41 (100) 0.115 to 0.017 0.1513
Improvement 1/41 (2.4) 0 0.023 to 0.072 0.3143
Failure 1/41 (2.4) 0 0.023 to 0.072 0.3143
Indeterminate 0 0 – –
Urine bacteriological outcomes, number of patient/total (%)
Eradication 26/41 (63.4) 24/40 (60) 0.178 to 0.246 0.7530
Persistence 2/41 (4.9) 2/40 (5) 0.095 to 0.093 0.9834
Superinfection 1/41 (2.4) 2/40 (5) 0.108 to 0.056 0.5345
Indeterminate 12/41 (29.3) 12/40 (30) 0.206 to 0.192 0.9450
Blood bacteriological outcomes, number of patient/total (%)
Eradication 10/11 (90.9) 6/6 (100) 0.261 to 0.079 0.4462
Persistence 0 0 – –
Superinfection 1/11 (9.1) 0 0.079 to 0.261 0.4462
Indeterminate 0 0 – –
95% CI, 95% conﬁdence interval.
Table 4
Most common drug-related clinical adverse effects reported during study drug
therapy
Symptom Group A (n = 41)a Group B (n = 41)a p-Value
Nausea 1 (2.4) 1 (2.4) 1.0000
Diarrhea 1 (2.4) 1 (2.4) 1.0000
Local IV reaction 2 (4.9) 0 0.1522
IV, intravenous.
a Data for each variable represent the number and percentage (in parenthesis),
unless otherwise indicated.
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susceptibility study.
3.4. Bacteriological efﬁcacy
3.4.1. Urine bacteriological outcome
The bacteriological response was ‘eradication’ for 63.4% (26/41
cases) of group A and 60% (24/40 cases) of group B (p = 0.75, 95% CI
0.18 to 0.25). The urine culture of one patient in group B showed
no growth on the enrollment date but the patient had E. coli
septicemia. The urine bacteriological response is shown in Table 3.
Four patients in total (two patients from each group) were
classiﬁed as ‘persistence’ because of persistent E. coli in the urine
culture at the follow-up visit. One patient from group A and two
patients from group B were classiﬁed as ‘superinfection’ because
their urine cultures presented 105 CFU/ml of Enterococcus spp.
Twelve patients in each group were classiﬁed as ‘indeterminate’
because urine cultures presented mixed organisms of two to six
different strains of any colony count.
3.4.2. Blood bacteriological outcome
Among those with bacteremia, 10 of 11 (90.9%) patients in
group A and six of six (100%) patients in group B had a favorable
microbiological response that was classiﬁed as bacteriological
eradication. One bacteremic patient was classiﬁed as having a
superinfection due to coagulase-negative staphylococci; no
patient had persistent bacteremia. All variables for the bloodbacteriological outcomes were similar between the two treatment
groups (p = NS).
3.5. Adverse events
AEs were observed in four patients in group A and two patients
in group B, giving incidences of 9.8% (4/41) and 4.9% (2/41),
respectively (Table 4). The AEs in group B were digestive symptoms
including nausea and diarrhea, while in group A, a local
intravenous reaction (phlebitis) was observed in two patients in
addition to digestive symptoms. The severity of the symptoms was
either mild or moderate. In all patients with AEs, the symptoms
resolved spontaneously and the treatment was continued without
any remedial action. Abnormal liver function test ﬁndings were not
noted in either group.
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Our study aimed to ﬁnd an oral antimicrobial agent that could
be substituted for ﬂuoroquinolones for the treatment of acute
pyelonephritis in the current era of high incidence QREC. In the
present study, as well as in previously reported studies,
Enterobacteriaceae accounted for the majority of pathogens.5,10,21
E. coli was the predominant single isolate in urine and blood
cultures, accounting for 83.5% and 82.4%, respectively. In addition,
this study demonstrated that 31.6% of community-acquired acute
pyelonephritis was caused by ﬂuoroquinolone-resistant E. coli.
Those strains were isolated from patients who had received prior
antimicrobial therapy within 1 month and had histories of upper or
lower UTIs within 6 months. In areas where the likelihood of
ﬂuoroquinolone resistance is high (>10%) and in women who have
risk factors for ﬂuoroquinolone resistance, the recommendation of
IDSA 2010 is a long-acting parenteral third-generation cephalo-
sporin such as ceftriaxone.5 Therefore, the patients in the present
study would beneﬁt from oral third-generation cephalosporins.
The present study was the ﬁrst to compare a 10-day regimen of
ceftriaxone versus a switch therapy from ceftriaxone to oral
cefditoren pivoxil for the treatment of acute pyelonephritis. The
overall clinical cure rate in group A was not signiﬁcantly different
from that in group B (95.1% vs. 100%; p = 0.15; 95% CI 0.12 to
0.02). A total of two out of 41 (4.9%) patients in group A were not
classiﬁed as clinically cured owing to one patient having clinical
failure and one patient who improved. Similar studies have been
performed by Sanchez et al. and Suankratay et al. – prospective
studies of ceftriaxone treatment in acute pyelonephritis caused by
non-ESBL-producing bacteria. The clinical failure rates averaged 4%
and 7%, respectively, rates that are consistent with this study.11,22
The two cases in this study exhibited risk factors including old age
and had underlying diabetes mellitus, complicated pyelonephritis,
and previous use of antimicrobials within 1 month. These might be
the clinical risk factors associated with antimicrobial-resistant
uropathogens, leading to important clinical failure.7,23,24 However,
no statistically signiﬁcant difference was seen among the risk
factors in the two treatment groups and no data on the risk factors
were shown in the studies of Sanchez et al. and Suankratay
et al.11,22 Other factors such as urinary tract stone or hydrone-
phrosis, particularly in elderly patients, may also have contributed
to the treatment failure in these two cases.
From this study, the clinical efﬁcacy of switch therapy from
ceftriaxone to cefditoren pivoxil was comparable to one of
ceftriaxone therapy, demonstrating that cefditoren pivoxil is
highly effective as a switch therapy in the management of acute
pyelonephritis. Many reasons could explain this. Firstly, cefditoren
pivoxil is the latest oral third-generation cephalosporin on the
market and thus has seldom been used for the treatment of UTIs.
Therefore, the MIC of the uropathogens to this drug may not be
elevated. Secondly, the inclusion criteria of this study meant the
enrollment only of patients whose infection was caused by a
uropathogen susceptible to ceftriaxone and cefditoren pivoxil, and
theoretically the high levels of cephalosporins in the urine may be
sufﬁcient to kill the organisms. Finally, the mean duration of acute
pyelonephritis symptoms in the two treatment groups was 2.6
days, which might be classiﬁed as early detection of the disease.
Other studies have had a mean duration of symptoms of 3–3.5
days.3,11,12,22 For these reasons, the clinical cure rate in the current
study was high. A similar study has been performed by Sanchez
et al., who conducted a prospective and randomized clinical trial of
women with acute uncomplicated pyelonephritis to compare the
short-term effectiveness of ceftriaxone single dose followed by
ceﬁxime as an oral third-generation cephalosporin with a standard
treatment. The clinical cure rate on the third day of ceftriaxone
single dose followed by ceﬁxime was 92%.11 Similar to the presentstudy, the clinical cure rate of ceftriaxone followed by cefditoren
pivoxil was 100%. It might be demonstrated that the clinical
response rate to cefditoren pivoxil is comparable to that of
ceﬁxime, which is the ﬁrst oral third-generation cephalosporin for
switch therapy in the treatment of this disease.25
The urine bacteriological eradication rate of group A was not
signiﬁcantly different from group B (63.4% vs. 60%; p = 0.75; 95% CI
0.18 to 0.25) in the treatment of acute pyelonephritis. This shows
that the success rates in the two treatment groups were similar and
consistent with the results of the primary outcome. Follow-up
blood cultures were obtained for all bacteremic patients. Results
showed that all bloodstream infections were eradicated. None had
persistent bacteremia, but one case in group A had a documented
bacterial superinfection with coagulase-negative staphylococci.
However, this case was not associated with clinical failure. In this
study, the urine bacteriological eradication rates in the two
treatment groups were lower than those found in other studies.
Conﬂicting results with regard to bacteriological eradication exist
in the literature, as reported by Sanchez et al.,11 Aarakawa et al.,26
and Wells et al.12 (100%, 85.7%, and 92.8%, respectively), probably
due to differences in study design, inclusion and exclusion criteria,
and operational deﬁnitions among these studies, particularly in
bacteriological eradication. Several studies have deﬁned bacterio-
logical eradication as eradication of the infecting strains or
uropathogen present at 105 CFU/ml at entry reduced to <104
CFU/ml.11,12,26 In the present study, the deﬁnition of eradication of
the infecting strain was ‘‘not found in the follow-up treatment in
any colony count or yielding sterile urine cultures (no growth)’’.
Findings other than these deﬁnitions were categorized into
‘indeterminate’. Furthermore, recurrent acute pyelonephritis
was also evaluated at 2 weeks after the end of treatment. The
results indicated that no recurrent acute pyelonephritis was
observed in either of the groups.
Regarding the strains identiﬁed after the end of treatment, P.
aeruginosa and Enterococcus spp, which had low susceptibility to
third-generation cephalosporin, were detected in 12 cases (two P.
aeruginosa and 10 enterococci). Enterococci were the most
common cause of new infections in both groups. However these
were not associated with clinical failure and could be classiﬁed
only as asymptomatic bacteriuria similar to other prospective
studies.12,26,27
The strengths of this study include its well-deﬁned design,
clearly deﬁned bacteriological eradication, which was classiﬁed as
eradication for urine culture only presenting with no growth,
evaluation of recurrent acute pyelonephritis at 2 weeks after the
end of treatment, no drop-out sample, a high rate of adherence to
medication, and inclusion of both uncomplicated and complicated
acute pyelonephritis. Also, both groups were made up of
hospitalized and non-hospitalized patients, allowing results to
be generalized to the general population.
However, this study has some potential weaknesses that should
be taken into consideration. Firstly, the study was only performed
at a single center in northeastern Thailand, which might be
different from other regions. The local antimicrobial susceptibility
patterns of E. coli in particular should be considered in the
treatment of this disease. Secondly, the study was limited to only
those patients with bacteriologically proven acute pyelonephritis
(positive culture). However, patients who clinically appear to have
acute pyelonephritis when bacteriological assessment is unavail-
able would be more relevant, particularly in an emergency
department (outpatients). Thirdly, in the case of fatal cases with
more severe infection, those with abnormalities of urinary tract
structures (urinary tract stone and hydronephrosis) or a retained
Foley’s catheter were excluded from the study. Therefore,
determination of the efﬁcacy of cefditoren pivoxil in these
conditions was limited. Finally, the oral and intravenous placebos
T. Monmaturapoj et al. / International Journal of Infectious Diseases 16 (2012) e843–e849 e849were distinguishable from the actual drugs, which may be a
confounding factor in the evaluation of clinical efﬁcacy.
In conclusion, the current trial demonstrated that treatment
regimens with intravenous ceftriaxone followed by oral cefditoren
pivoxil 400 mg once daily after clinical improvement is highly
effective and well-tolerated for the treatment of patients with
acute pyelonephritis, even for uropathogens with a high propor-
tion of quinolone-resistant strains. Therefore, this could be used as
the initial treatment, with ceftriaxone and switch therapy to
cefditoren pivoxil. However, consideration of antimicrobial resis-
tance – the local antimicrobial susceptibility patterns of E. coli in
particular – should be considered in the management of this
disease, as the resistance patterns of E. coli strains causing acute
pyelonephritis vary considerably between regions and countries.
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